4/1
08:23 am
dare
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
3/31
04:01 pm
dare
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
Low
Report
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
3/24
08:00 am
dare
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
Neutral
Report
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
2/20
08:00 am
dare
Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
Medium
Report
Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant
2/6
08:00 am
dare
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
High
Report
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
1/9
08:00 am
dare
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference